Premium
Long‐term results of first‐line sequential high‐dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor
Author(s) -
Miki Tsuneharu,
Mizutani Yoichi,
Akaza Hideyuki,
Ozono Seiichiro,
Tsukamoto Taiji,
Terachi Toshiro,
Naito Katsusuke,
omura Norio,
Hara Isao,
Yoshida Osamu
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2006.01655.x
Subject(s) - medicine , etoposide , carboplatin , ifosfamide , chemotherapy , testicular germ cell tumor , regimen , germ cell tumors , chemotherapy regimen , oncology , progressive disease , urology , gastroenterology , testicular cancer , surgery , cisplatin
Objective: Standard chemotherapy shows relatively low long‐term survival in patients with poor‐risk testicular germ cell tumor (GCT). First‐line high‐dose chemotherapy (HD‐CT) may improve the result. High‐dose carboplatin, etoposide, ifosfamide chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) was investigated as first‐line chemotherapy in patients with advanced testicular GCT. Methods: Fifty‐five previously untreated testicular GCT patients with Indiana ‘advanced disease’ criteria received three cycles of bleomycin, etoposide and cisplatin (BEP) followed by one cycle of HD‐CT plus PBSCT, if elevated serum tumor markers were observed after three cycles of the BEP regimen. Results: Thirty patients were treated with BEP alone, because the tumor marker(s) declined to normal range. Twenty‐five patients received BEP and HD‐CT. One patient died of rhabdomyolysis due to HD‐CT. Three and six (13% and 25%) out of 24 patients treated with BEP and HD‐CT achieved marker‐negative and marker‐positive partial responses, respectively. The other patients achieved no change. Fifteen (63%) are alive and 14 (58%) are free of disease at a median follow‐up time of 54 months. Severe toxicity included treatment‐related death (4%). Conclusions: HD‐CT with peripheral stem cell support can be successfully applied in a multicenter setting. HD‐CT demonstrated modest anticancer activity for Japanese patients with advanced testicular GCT and was well tolerated. This regimen might be examined for further investigation in randomized trials in first‐line chemotherapy for patients with poor‐risk testicular GCT.